Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' Income from Continuing Operations fell 11712.7% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 9594.62%. This contributed to the annual value of -$322.1 million for FY2024, which is 5218.07% down from last year.
  • Per Avidity Biosciences' latest filing, its Income from Continuing Operations stood at -$174.1 million for Q3 2025, which was down 11712.7% from -$156.7 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Income from Continuing Operations high stood at -$23.8 million for Q1 2021, and its period low was -$174.1 million during Q3 2025.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$52.1 million (2023), whereas its average is -$66.9 million.
  • In the last 5 years, Avidity Biosciences' Income from Continuing Operations crashed by 29179.95% in 2021 and then tumbled by 257.18% in 2023.
  • Over the past 5 years, Avidity Biosciences' Income from Continuing Operations (Quarter) stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then dropped by 19.59% to -$60.3 million in 2023, then crashed by 69.81% to -$102.5 million in 2024, then tumbled by 69.89% to -$174.1 million in 2025.
  • Its Income from Continuing Operations was -$174.1 million in Q3 2025, compared to -$156.7 million in Q2 2025 and -$115.3 million in Q1 2025.